# US 2025/0059245 A1 · Nucleic acid structure utilizing snare

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0059245 A1
- Document ID: US20250059245A1
- Status: Published application
- Kind: A1
- Application number: 18/681,277
- Filed: 2022-08-05
- Published: 2025-02-20
- Earliest claimed: 2021-08-06
- Assignees: Kao Corporation
- Applicants: Kao Corporation
- Inventors: Keimon SAYAMA; Takaya SUGANUMA; Satoshi HORI; Shun KUBO; Masaki YAMAMOTO; Satoko FUKAGAWA; Junko ISHIKAWA
- Web page: https://patentgrep.com/patent/US20250059245A1

## CPC

- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001153: {Wilms tumor 1 [WT1]}
- A61K 39/35: Allergens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/435: from animals; from humans
- C07K 14/47: from mammals
- C07K 14/4705: {stimulating, promoting or activating activity}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/85: for animal cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- A61K 2039/6031: {Proteins}
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided is a nucleic acid structure which enhances an antigen-specific immune response. The nucleic acid structure comprises a polynucleotide encoding a SNARE protein, a polynucleotide encoding a proprotein convertase recognition sequence, and a polynucleotide encoding an antigen, wherein the polynucleotide encoding a SNARE protein and the polynucleotide encoding an antigen are linked via the polynucleotide encoding a proprotein convertase recognition sequence.

## Claims

### Claim 1

A nucleic acid structure comprising a polynucleotide encoding a SNARE protein, a polynucleotide encoding a proprotein convertase recognition sequence, and a polynucleotide encoding an antigen, wherein the polynucleotide encoding a SNARE protein and the polynucleotide encoding an antigen are linked via the polynucleotide encoding a proprotein convertase recognition sequence.

### Claim 2 (depends on 1)

The nucleic acid structure according to claim 1, wherein the polynucleotide encoding an antigen is linked downstream of the polynucleotide encoding a SNARE protein via the polynucleotide encoding a proprotein convertase recognition sequence.

### Claim 3 (depends on 1)

The nucleic acid structure according to claim 1, wherein the polynucleotide encoding an antigen is linked downstream of the polynucleotide encoding a SNARE protein via the polynucleotide encoding a proprotein convertase recognition sequence and a polynucleotide encoding a linker.

### Claim 4 (depends on 1)

The nucleic acid structure according to claim 1, which is a plasmid vector, mRNA or a virus vector.

### Claim 5 (depends on 1)

The nucleic acid structure according to claim 1, wherein the antigen is at least one selected from the group consisting of a cancer antigen, an autoantigen, a bacterial antigen, a fungal antigen, a protozoan antigen and an allergen.

### Claim 6 (depends on 1)

An antigen-specific Th1-type immune response inducing or enhancing agent comprising, as an active component, the nucleic acid structure according to claim 1.

### Claim 7 (depends on 1)

An antigen-specific cellular immune response inducing or enhancing agent comprising, as an active component, the nucleic acid structure according to claim 1.

### Claim 8 (depends on 1)

A nucleic acid vaccine comprising, as an active component, the nucleic acid structure according to claim 1.

### Claim 9 (depends on 8)

The nucleic acid vaccine according to claim 8, which induces or enhances an antigen-specific Th1-type immune response.

### Claim 10 (depends on 8)

The nucleic acid vaccine according to claim 8, which induces or enhances an antigen-specific cellular immune response.

### Claim 11 (depends on 8)

The nucleic acid vaccine according claim 8, which is cancer vaccine, wherein the antigen is at least one selected from the group consisting of cancer antigens.

### Claim 12 (depends on 8)

The nucleic acid vaccine according claim 8, which is a vaccine for prevention or treatment of an allergy, wherein the antigen is at least one selected from the group consisting of allergens.

### Claim 13 (depends on 8)

The nucleic acid vaccine according to claim 8, which is a vaccine for treatment of an autoimmune disease, wherein the antigen is at least one selected from the group consisting of autoantigens.

### Claim 14 (depends on 8)

The nucleic acid vaccine according to claim 8, which is administered orally or parenterally.
